RESEARCH-USE BIOSIMILAR ANTIBODY

Osemitamab

Monoclonal antibody · IgG1

CLDN18.2IgG1RUO

Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.

TARGETCLDN18.2
YMonoclonal antibody
CATALOGSC-BS-295
CATALOG NUMBERSC-BS-295
MOLECULAR WEIGHTApprox. 146.5 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.

Osemitamab is a recombinant research-use antibody directed against CLDN18.2.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte